90Y-CA/SPIONs for dual magnetic hyperthermia-radionuclide nanobrachytherapy of solid tumours

Vukadinović, Aleksandar; Milanović, Zorana; Ognjanović, Miloš; Janković, Drina; Radović, Magdalena; Mirković, Marija; Karageorgou, Maria-Argyro; Bouziotis, Penelope; Erić, Suzana; Djurić, Sladjana; Antić, Bratislav; Prijović, Željko

doi:10.1088/1361-6528/ac7ac0

Cited by 10 publications

(15 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The presented time dependencies demonstrate that the coating of SPION–citrate with the Au layer slightly improves the heat generation capability of nanoparticles. However, the attachment of long PEG chains considerably lessens the SAR value, probably because of changes in the hydrodynamic diameter and, thus Brownian losses as well as changes in the saturation magnetization value [ 30 ]. Nevertheless, as shown in Figure 5 a concentration of SPION@Au–PEG nanoparticles greater than 6 mg/mL enables the quick achievement of the temperature required for cell apoptosis or necrosis.…”

Section: Resultsmentioning

confidence: 99%

198Au-Coated Superparamagnetic Iron Oxide Nanoparticles for Dual Magnetic Hyperthermia and Radionuclide Therapy of Hepatocellular Carcinoma

Gharibkandi

Żuk

Müftüler

et al. 2023

IJMS

View full text Add to dashboard Cite

This study was performed to synthesize a radiopharmaceutical designed for multimodal hepatocellular carcinoma (HCC) treatment involving radionuclide therapy and magnetic hyperthermia. To achieve this goal, the superparamagnetic iron oxide (magnetite) nanoparticles (SPIONs) were covered with a layer of radioactive gold (198Au) creating core–shell nanoparticles (SPION@Au). The synthesized SPION@Au nanoparticles exhibited superparamagnetic properties with a saturation magnetization of 50 emu/g, which is lower than reported for uncoated SPIONs (83 emu/g). Nevertheless, the SPION@Au core–shell nanoparticles showed a sufficiently high saturation magnetization value which allows them to reach a temperature of 43 °C at a magnetic field frequency of 386 kHz. The cytotoxic effect of nonradioactive and radioactive SPION@Au–polyethylene glycol (PEG) bioconjugates was carried out by treating HepG2 cells with various concentrations (1.25–100.00 µg/mL) of the compound and radioactivity in range of 1.25–20 MBq/mL. The moderate cytotoxic effect of nonradioactive SPION@Au-PEG bioconjugates on HepG2 was observed. The cytotoxic effect associated with the β− radiation emitted by 198Au was much greater and already reaches a cell survival fraction below 8% for 2.5 MBq/mL of radioactivity after 72 h. Thus, the killing of HepG2 cells in HCC therapy should be possible due to the combination of the heat-generating properties of the SPION-198Au–PEG conjugates and the radiotoxicity of the radiation emitted by 198Au.

show abstract

Section: Resultsmentioning

confidence: 99%

198Au-Coated Superparamagnetic Iron Oxide Nanoparticles for Dual Magnetic Hyperthermia and Radionuclide Therapy of Hepatocellular Carcinoma

Gharibkandi

Żuk

Müftüler

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…The major drawback of this process is that the metal complex can be dissociated within the biological system due to enzymatic action. A few examples of chelators are dodecane tetra acetic acid-based chelators (DOTA) (used for 68 Ga, 111 In, 188 Re labeling), 1,4,7- triazacyclononane-N,N′,N″-triacetic acid-based chelators (NOTA) (used for 67 Ga/ 68 Ga and 64 Cu labeling), diethylenetriaminepentaacetic acid based chelators (DTPA) (used for 99m Tc, 111 In, and 68 Ga labeling), etc. 45 Another approach in chelator-based radiolabeling is the ionophore-based method, wherein an ionophore ligand forms an ionophore complex with a radiometal.…”

Section: Chelator-based Radiolabelingmentioning

confidence: 99%

“…Vukadinović et al synthesized citrate coated, flower shaped, superparamagnetic iron oxide NPs (CA/SPIONs) labeled with 90 Y for dual magnetic hyperthermia and nanobrachytherapy to treat solid cancer . The toxicity limit of CA/SPIONs was observed to be up to 1.0 mg mL –1 in mouse colon cancer cells.…”

Section: Preclinical Studiesmentioning

confidence: 99%

“…In comparison to surface labeling of NPs, this strategy is more advantageous as high RCS is achieved. Examples of common ionophores include oxine ( 111 In, 225 Ac, 177 Lu labeling), acetylacetone ( 111 In labeling), A23187 ( 111 In, 90 Y labeling) etc. 46 The primary concern of chelator-based radiolabeling is 2-fold: the potential leaching of radiometals from the complex by dissociation in vivo and the potential alteration of the physicochemical properties of NPs following chelation.…”

Section: Chelator-based Radiolabelingmentioning

confidence: 99%

See 1 more Smart Citation

Cancer Brachytherapy at the Nanoscale: An Emerging Paradigm

Ghosh,

Lee,

Hsu

et al. 2023

Chemical & Biomedical Imaging

View full text Add to dashboard Cite

Brachytherapy is an established treatment modality that has been globally utilized for the therapy of malignant solid tumors. However, classic therapeutic sealed sources used in brachytherapy must be surgically implanted directly into the tumor site and removed after the requisite period of treatment. In order to avoid the trauma involved in the surgical procedures and prevent undesirable radioactive distribution at the cancerous site, welldispersed radiolabeled nanomaterials are now being explored for brachytherapy applications. This emerging field has been coined "nanoscale brachytherapy". Despite present-day advancements, an ongoing challenge is obtaining an advanced, functional nanomaterial that concurrently incorporates features of high radiolabeling yield, short labeling time, good radiolabeling stability, and long tumor retention time without leakage of radioactivity to the nontargeted organs. Further, attachment of suitable targeting ligands to the nanoplatforms would widen the nanoscale brachytherapy approach to tumors expressing various phenotypes. Molecular imaging using radiolabeled nanoplatforms enables noninvasive visualization of cellular functions and biological processes in vivo. In vivo imaging also aids in visualizing the localization and retention of the radiolabeled nanoplatforms at the tumor site for the requisite time period to render safe and effective therapy. Herein, we review the advancements over the last several years in the synthesis and use of functionalized radiolabeled nanoplatforms as a noninvasive substitute to standard brachytherapy sources. The limitations of present-day brachytherapy sealed sources are analyzed, while highlighting the advantages of using radiolabeled nanoparticles (NPs) for this purpose. The recent progress in the development of different radiolabeling methods, delivery techniques and nanoparticle internalization mechanisms are discussed. The preclinical studies performed to date are summarized with an emphasis on the current challenges toward the future translation of nanoscale brachytherapy in routine clinical practices.

show abstract

“…For this reason, several papers [ 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 ] have reported the synthesis and in vivo application of radiolabeled Fe 3 O 4 nanoparticles as potential SPECT/MRI or PET/MRI DMCAs. In some cases, these DMCAs may also be used for drug delivery and magnetic hyperthermia to achieve both diagnosis and therapy of cancer [ 17 , 18 , 19 , 20 , 21 ].…”

Section: Introductionmentioning

confidence: 99%

99mTc-Labeled Iron Oxide Nanoparticles as Dual-Modality Contrast Agent: A Preliminary Study from Synthesis to Magnetic Resonance and Gamma-Camera Imaging in Mice Models

et al. 2022

Self Cite

View full text Add to dashboard Cite

The combination of two imaging modalities in a single agent has received increasing attention during the last few years, since its synergistic action guarantees both accurate and timely diagnosis. For this reason, dual-modality contrast agents (DMCAs), such as radiolabeled iron oxide (namely Fe3O4) nanoparticles, constitute a powerful tool in diagnostic applications. In this respect, here we focus on the synthesis of a potential single photon emission computed tomography/magnetic resonance imaging (SPECT/MRI) DMCA, which consists of Fe3O4 nanoparticles, surface functionalized with 2,3-dicarboxypropane-1,1-diphosphonic acid (DPD) and radiolabeled with 99mTc, [99mTc]Tc-DPD-Fe3O4. The in vitro stability results showed that this DMCA is highly stable after 24 h of incubation in phosphate buffer saline (~92.3% intact), while it is adequately stable after 24 h of incubation with human serum (~67.3% intact). Subsequently, [99mTc]Tc-DPD-Fe3O4 DMCA was evaluated in vivo in mice models through standard biodistribution studies, MR imaging and gamma-camera imaging. All techniques provided consistent results, clearly evidencing noticeable liver uptake. Our work documents that [99mTc]Tc-DPD-Fe3O4 has all the necessary characteristics to be a potential DMCA.

show abstract

90Y-CA/SPIONs for dual magnetic hyperthermia-radionuclide nanobrachytherapy of solid tumours

Cited by 10 publications

References 65 publications

198Au-Coated Superparamagnetic Iron Oxide Nanoparticles for Dual Magnetic Hyperthermia and Radionuclide Therapy of Hepatocellular Carcinoma

198Au-Coated Superparamagnetic Iron Oxide Nanoparticles for Dual Magnetic Hyperthermia and Radionuclide Therapy of Hepatocellular Carcinoma

Cancer Brachytherapy at the Nanoscale: An Emerging Paradigm

99mTc-Labeled Iron Oxide Nanoparticles as Dual-Modality Contrast Agent: A Preliminary Study from Synthesis to Magnetic Resonance and Gamma-Camera Imaging in Mice Models

Contact Info

Product

Resources

About